Immunovaccine Announces Results of 2014 Annual General Meeting

HALIFAX, NOVA SCOTIA -- (Marketwired) -- 04/24/14 -- Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX VENTURE:IMV), a clinical stage vaccine company, today announced the results of the Company's Annual General Meeting (AGM) of shareholders held on April 23, 2014.

During the AGM, the shareholders re-elected James W. Hall, Llew Keltner, Ph.D., Stephanie Léouzon, Marc Mansour, Ph.D., Wayne Pisano, Bradley Thompson, Ph.D., and Albert Scardino to serve on the board of directors until the next annual meeting of shareholders. Mr. Scardino will also continue his duties as executive chairman of the board. Wade K. Dawe retired from the board after nine years as a director.

"The Board and management wish to thank Wade for his service and contributions to the Board," said Mr. Scardino.

Additionally, Kimberly Stephens, Immunovaccine's Chief Financial Officer, has been re-appointed Corporate Secretary.

The shareholders approved all motions put forth at the meeting including the appointment of PricewaterhouseCoopers LLP, Chartered Accountants, as the Company's independent auditors.

About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvants to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in 2014, in ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax.

Connect at:

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Immunovaccine Inc.
Kimberly Stephens
(902) 492-1819
Vida Strategic Partners (media)
Tim Brons
(415) 675-7402

Source: Immunovaccine Inc.